September 9, 2022
RegMed Investors’ (RMi) pre-open: share pricing runs
September 8, 2022
RegMed Investors’ (RMi) pre-open: yesterday’s added value was a gift
September 7, 2022
RegMed Investors’ (RMi) pre-open: the issues; resistance, the lack of support, conviction and relative strength
September 6, 2022
RegMed Investors’ (RMi) pre-open: Warning, cell and gene therapy sector equities!
August 31, 2022
RegMed Investors’ (RMi) pre-open: August is over as the cell and gene therapy sector has not quite found its footing
August 30, 2022
RegMed Investors (RMI): burning investors, Applied Genetic Technologies (AGTC)
August 30, 2022
RegMed Investors’ (RMi) pre-open: time for some bounce, although algos are still hungry
August 29, 2022
RegMed Investors’ (RMi) pre-open: Ripping-off shareholders as share pricing declines, inclines and degenerates
August 26, 2022
RegMed Investors’ (RMi) closing bell: back to bottom dragging with share pricing as weight sinkers
August 19, 2022
RegMed Investors’ (RMi) closing bell: feeling the low while experiencing “positioning complexity”
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors